RenovoRx Updates Pivotal TIGeR-PaC Trial of Pancreatic Cancer Treatment
RenovoRx, Inc. announced an update of its ongoing pivotal phase 3 TIGeR-PaC trial, which is evaluating the company’s first investigational drug-device combination oncology product candidate, which uses RenovoRx’s TAMP transarterial microperfusion therapy platform enabled by its RenovoCath for the treatment of locally advanced pancreatic cancer.